Early Stage Biotechnology Company CLYZ Labs receives HMRC Advanced Assurance for SEIS/EIS Scheme(s)
CLYZ Labs is pleased to announce that it has received the HMRC Advanced Assurance for SEIS/EIS Scheme(s).
The Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS) are government initiatives offering some of the most attractive tax breaks available in the UK. For the investor, it’s a tax efficient way to invest in small companies.
The EIS is aimed at the wealthier, sophisticated investors. People can invest up to £1,000,000 in any tax year and receive 30% tax relief. However, they are locked into the scheme for a minimum of three years. EIS seeks to encourage investment into unlisted companies.
“Being able to achieve the successful Advanced Assurance from HMRC in record time without having to answer additional queries, is a testament to the business planning work completed by the Founders and to the team at Sapphire Capital Partners LLP who assisted us in achieving this feat. Clyz Labs is committed to create a significant shareholder value; and having qualified for the government initiatives – The Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS)- is an attractive incentive for investors to back the Clyz Mission to accelerate the development of new and existing therapies for the Cancer patients in UK and worldwide.” said Dr Himanshu Kataria – the founder & CEO of CLYZ labs.
Boyd Carson, Partner at Sapphire Capital Partners LLP added “Robust business plan and other preparatory work done by Clyz’s Directors helped us achieve this successful HMRC Advanced assurance within 5 weeks. We wish Clyz Labs every success in their mission to improve the health of cancer patients.”
Please do not hesitate to contact Zalak.Kataria@clyzlabs.co.uk if you need any further information.
CLYZ Labs is an early stage biotechnology company based in United kingdom. Its mission is to collaboratively leverage existing cutting-edge technological innovations to improve the quality of life and survival of cancer patients by our work in clinical and pre-clinical stages of cancer therapies. Clyz Labs vision is to provide every cancer patient with our specialised diagnostic test to Personalised Therapy leading to improved quality of life and overall survival backed by reliable clinical trials. Clyz labs is committed to provide accurate, reliable, validated laboratory results to guide the Personalised Therapy for the Cancer patient.
Sapphire Capital Partners LLP is authorised and regulated by the Financial Conduct Authority. It specialises in tax efficient schemes (such as SEIS, EIS, VCT & SITR) to grow companies and investment funds. It assist clients in achieving SEIS, EIS and SITR HMRC advance assurance, raise funds and act as an FCA approved investment manager to SEIS, EIS & SITR funds as well as Alternative Investment Funds.